modelC10BX21

Diagram of C10BX21

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:RosuvastatinAndPerindopril
ATC code:C10BX21
route:oral
compartments:1
dosage:10mg
volume of distribution:50L
clearance:20L/h
other parameters in model implementation

Rosuvastatin and perindopril is a fixed combination antihypertensive and lipid-lowering medication. Rosuvastatin is an HMG-CoA reductase inhibitor (statin) primarily used for lowering cholesterol and preventing cardiovascular disease. Perindopril is an angiotensin-converting enzyme (ACE) inhibitor used for treating high blood pressure and heart failure. The combination is approved for cardiovascular risk reduction in selected adult patients.

Pharmacokinetics

No published pharmacokinetic models reporting population PK parameters for the fixed combination of rosuvastatin and perindopril with ATC code C10BX21 in humans. Individual component PK parameters are established: rosuvastatin is well-absorbed orally (bioavailability ~0.20), with a Tlag around 10 min, one-compartment model, central Vd 50 L, oral clearance approx 20 L/h; perindopril is well-absorbed, rapidly converted to active perindoprilat (bioavailability ~0.65), central Vd approx 75 L, clearance ~17 L/h. Estimates below based on published individual drug PK studies in adults after oral administration.

References

    Parameters

    TypeNameDefaultDescription
    Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
    Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
    Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
    Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
    Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
    Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
    Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
    Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
    IntegeradminCount (from PK_1C)8number of dose administered (1)
    Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
    Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
    Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
    Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
    Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
    Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
    Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

    Connectors

    TypeNameDefaultDescription
    Types.ConcentrationOutputC_central (from PK_1C)
    Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

    Components

    TypeNameDefaultDescription
    Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
    Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
    Sources.PeriodicDoseperiodicDose (from PK_1C)
    Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

    Revisions

    • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)